
    
      The maximum duration for GLP1-RA participants was approximately 29 weeks: up to 2 week
      screening period, a 26 week treatment period (either randomized or uncontrolled), and a 3 or
      9 day post-treatment safety follow-up period.

      Maximum duration for FRC participants was approximately 55 weeks: up to 2-week screening
      period, a 26-week randomized treatment period, a 26-week extension period and a 3-day
      post-treatment safety follow-up period.

      All primary and secondary efficacy, safety and other outcome measures were assessed at the
      end of the extension period.
    
  